anti-TFPI

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy
Pharmaceutical Business Review
Tue, 11/24/20 - 10:23 am
Pfizer
clinical trials
marstacimab
hemophilia
anti-TFPI